Adc Therapeutics Sa Quick Ratio (ADCT) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Adc Therapeutics Sa  (NYSE: ADCT)

Adc Therapeutics Sa's Quick Ratio

ADCT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 2.54 below Adc Therapeutics Sa average.

Within Major Pharmaceutical Preparations industry 256 other companies have achieved higher Quick Ratio than Adc Therapeutics Sa in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 309, from total ranking in the first quarter 2026 at 689.

Explain Quick Ratio?
How much Cash & cash equivalents ADCT´s has?
What are ADCT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ADCT Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 452.98 % -27.53 % -17.65 % -33.58 % -16.94 %
Y / Y Cash & cash equivalent Change -17.18 % 18.65 % 4.17 % -14.41 % -11.85 %
Quick Ratio MRQ 2.54 15.86 8.11 13.86 16.95
ADCT's Total Ranking # 309 # 689 # 378 # 312 # 557
Seq. Current Liabilities Change 492.65 % -54.8 % 90.29 % 8.49 % -22.33 %
Seq. Cash & cash equivalent Change -5.15 % -11.61 % 11.33 % -11.27 % 35.88 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 257
Healthcare Sector # 443
Overall Market # 1236


Quick Ratio Statistics
High Average Low
35.72 6.95 1.23
(Mar 31 2023)   (Jan 31, 2008)




Financial Statements
Adc Therapeutics Sa's Current Liabilities $ 86 Millions Visit ADCT's Balance sheet
Adc Therapeutics Sa's Cash & cash equivalent $ 219 Millions Visit ADCT's Balance sheet
Source of ADCT's Sales Visit ADCT's Sales by Geography


Cumulative Adc Therapeutics Sa's Quick Ratio

ADCT's Quick Ratio for the trailling 12 Months

ADCT Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 49.54 % -23.36 % -18.21 % -33.93 % -18.02 %
Y / Y Cash & cash equivalent TTM Growth -3.88 % -2.78 % -9.83 % -13.1 % -12.37 %
Quick Ratio TTM 6.31 12.5 11.26 10.29 9.81
Total Ranking TTM # 422 # 459 # 326 # 314 # 313
Seq. Current Liabilities TTM Growth 89.13 % -6.52 % -7.53 % -8.53 % -3.08 %
Seq. Cash & cash equivalent TTM Growth -4.58 % 3.8 % 1.11 % -4.02 % -3.49 %

Quick ratio ranking by company, industry and sector >> Back to ADCT Financial Strength Comparisons >> Go to Compare ADCT Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q2 2026 to $86.33 millions, cumulative Quick Ratio decreased to 6.31 above the ADCT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 427 other companies have achieved higher Quick Ratio than Adc Therapeutics Sa. While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3640.

Explain Quick Ratio?
How much Cash & cash equivalents ADCT´s has?
What are ADCT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 428
Healthcare Sector # 871
Within the Market # 309


trailing twelve months Quick Ratio Statistics
High Average Low
10.86 3.39 0.32
(Dec 31 2020)   (Oct. 31, 2005)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Arvinas Inc   6.88 $ 567.900  Millions$ 82.500  Millions
Summit Therapeutics Inc   6.67 $ 690.749  Millions$ 103.566  Millions
Alumis inc   6.59 $ 502.300  Millions$ 76.233  Millions
Novelos Therapeutics, Inc.  6.49 $ 33.994  Millions$ 5.238  Millions
Genprex Inc   6.47 $ 15.154  Millions$ 2.342  Millions
Lisata Therapeutics Inc   6.45 $ 19.277  Millions$ 2.987  Millions
Larimar Therapeutics Inc   6.44 $ 219.880  Millions$ 34.166  Millions
United Therapeutics Corporation  6.13 $ 3,724.700  Millions$ 607.800  Millions
Serina Therapeutics Inc   6.12 $ 23.024  Millions$ 3.762  Millions
Revelation Biosciences Inc   6.11 $ 11.483  Millions$ 1.880  Millions
Spero Therapeutics Inc   6.02 $ 50.774  Millions$ 8.428  Millions
Aquestive Therapeutics Inc   5.98 $ 98.490  Millions$ 16.478  Millions
Xencor Inc  5.94 $ 486.350  Millions$ 81.865  Millions
Zymeworks Inc   5.73 $ 270.699  Millions$ 47.243  Millions
Tonix Pharmaceuticals Holding Corp   5.72 $ 176.232  Millions$ 30.785  Millions
Emmis Acquisition Corp   5.72 $ 0.708  Millions$ 0.124  Millions
Arcturus Therapeutics Holdings Inc   5.71 $ 191.483  Millions$ 33.536  Millions
Hoth Therapeutics Inc   5.70 $ 7.892  Millions$ 1.384  Millions
Silence Therapeutics Plc  5.67 $ 72.100  Millions$ 12.714  Millions
Adial Pharmaceuticals Inc   5.51 $ 28.200  Millions$ 5.121  Millions
Corbus Pharmaceuticals Holdings Inc   5.49 $ 117.941  Millions$ 21.483  Millions
Bio Green Med Solution Inc   5.48 $ 3.790  Millions$ 0.692  Millions
Arrowhead Pharmaceuticals Inc   5.47 $ 1,551.301  Millions$ 283.346  Millions
Context Therapeutics Inc   5.45 $ 42.990  Millions$ 7.885  Millions
Annexon Inc   5.44 $ 209.200  Millions$ 38.482  Millions
Mereo Biopharma Group Plc  5.37 $ 30.506  Millions$ 5.677  Millions
Cns Pharmaceuticals Inc   5.35 $ 19.985  Millions$ 3.738  Millions
Neurogene Inc   5.23 $ 112.485  Millions$ 21.505  Millions
Lexaria Bioscience Corp   5.20 $ 3.642  Millions$ 0.701  Millions
Barinthus Biotherapeutics Plc  5.19 $ 59.295  Millions$ 11.423  Millions

Date modified: 2026-09-26T07:39:03+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.